The Federal Circuit's ruling in Jazz Pharmaceuticals v. Avadel underscores the protections afforded to pharmaceutical companies under the Hatch-Waxman Act, particularly regarding injunctive relief. The court determined that a district court cannot enjoin a company from conducting clinical trials or seeking open-label extensions, even when patent infringement has been identified. This decision emphasizes the judicial protection of pharmaceutical research activities and the allowance for companies to pursue new drug indications without the threat of injunctions based on existing patent rights.
The Federal Circuit reaffirms that under the Hatch-Waxman Act's safe harbor provision, pharmaceutical companies cannot be enjoined from new clinical trials even if their products infringe patents.
The appellate court clarified that injunctive relief under 271(e) is limited, ensuring that companies retain the ability to conduct research and seek FDA approval for new drug indications.
Collection
[
|
...
]